文献速递妇科

非子宫内膜样子宫内膜癌女性微创子宫切除术的使用与结局

Use and outcomes of minimally invasive hysterectomy for women with nonendometrioid endometrial cancers.
PubMed 文献 · Am J Obstet Gynecol · 2018-08-04

该研究利用美国国家癌症数据库纳入2010至2014年接受子宫切除术的I-III期子宫癌女性,比较微创与开腹子宫切除术在非子宫内膜样亚型中的使用趋势及生存结局。经倾向评分逆概率加权分析,各非子宫内膜样亚型的微创手术与30天、90天及总死亡率均无关联。

要点

  • 非子宫内膜样子宫内膜癌中微创子宫切除术使用率2010至2014年间持续上升。
  • 浆液性癌57.6%、透明细胞癌57.0%、肉瘤47.3%接受微创子宫切除术。
  • 各非子宫内膜样亚型中,手术路径与30天、90天及总死亡率均无关联。

核心结论

  • I-III期非子宫内膜样子宫内膜癌女性中微创手术使用迅速增加,且微创手术似乎不 adverse 影响生存。

研究设计与样本

  • 基于美国国家癌症数据库的回顾性队列研究,纳入2010至2014年接受子宫切除术的I-III期子宫癌女性共94,507例,按组织学亚型分析微创与开腹手术,并行倾向评分逆概率加权分析。

主要发现

  • 94,507例患者中64,417例(68.2%)接受微创子宫切除术。
  • 子宫内膜样肿瘤(n=81,115)中70.8%接受微创手术;非子宫内膜样肿瘤(n=13,392)中浆液性癌57.6%、透明细胞癌57.0%、肉瘤47.3%、平滑肌肉瘤32.2%、间质肉瘤47.9%、癌肉瘤48.5%接受微创手术。
  • 2010至2014年间所有组织学亚型的微创手术使用率均增加;至2014年,非子宫内膜样亚型中机器人辅助手术占微创子宫切除术的47.9%至75.7%。
  • 多变量模型中,非子宫内膜样肿瘤女性接受微创手术的可能性低于子宫内膜样肿瘤女性(P<.05)。
  • 各非子宫内膜样组织学亚型中,手术路径与30天、90天或总死亡率均无关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimally invasive hysterectomy is now used routinely for women with uterine cancer. Most studies of minimally invasive surgery for endometrial cancer have focused on low-risk endometrioid tumors, with few reports of the safety of the procedure for women with higher risk histologic subtypes. OBJECTIVE: The purpose of this study was to examine the use of and survival associated with minimally invasive hysterectomy for women with uterine cancer and high-risk histologic subtypes. STUDY DESIGN: We used the National Cancer Database to identify women with stages I-III uterine cancer who underwent hysterectomy from 2010-2014. Women with serous carcinomas, clear cell carcinomas, and sarcomas were examined. Women who had laparoscopic or robotic-assisted hysterectomy were compared with those who underwent open abdominal hysterectomy. After a propensity score inverse probability of treatment weighted analysis, the effect of minimally invasive hysterectomy on overall, 30-day, and 90-day mortality rates was examined for each histologic subtype of uterine cancer. RESULTS: Of 94,507 patients who were identified, 64,417 patients (68.2%) underwent minimally invasive hysterectomy. Among women with endometrioid tumors (n=81,115), 70.8% underwent minimally invasive hysterectomy. The rates of minimally invasive surgery in those women with nonendometrioid tumors (n=13,392) was 57.6% for serous carcinomas, 57.0% for clear cell tumors, 47.3% for sarcomas, 32.2% for leiomyosarcomas, 47.9% for stromal sarcomas, and 48.5% for carcinosarcomas. Performance of minimally invasive surgery increased across all histologic subtypes between 2010 and 2014. For nonendometrioid subtypes, robotic-assisted procedures accounted for 47.9-75.7% of minimally invasive hysterectomies by 2014. In a multivariable model, women with nonendometrioid tumors were less likely to undergo minimally invasive surgery than those with endometrioid tumors (P<.05). There was no association between route of surgery and 30-day, 90-day, or overall mortality rates for any of the nonendometrioid histologic subtypes. CONCLUSION: The use of minimally invasive surgery is increasing rapidly for women with stage I-III nonendometrioid uterine tumors. Performance of minimally invasive surgery does not appear to impact survival adversely.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Nieto VL, Huang Y, Hou JY, et al. Use and outcomes of minimally invasive hysterectomy for women with nonendometrioid endometrial cancers. Am J Obstet Gynecol. 2018. PMID: 30086293. doi:10.1016/j.ajog.2018.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。